期刊文献+

紫杉醇联合顺铂并配合整体护理治疗复发性卵巢癌的疗效观察 被引量:2

下载PDF
导出
摘要 目的探讨紫杉醇联合顺铂方案配合整体护理治疗复发性卵巢癌的效果。方法将80例复发性卵巢癌手术患者随机分为研究组和对照组各40例,研究组采取紫杉醇及顺铂方案治疗,对照组仅采用顺铂单一化疗。2组患者均给予相应的整体护理,比较2组疗效及不良反应发生情况。结果研究组总有效率为70%,对照组总有效率为45%,研究组治疗效果明显优于对照组(P<0.05);2组不良反应发生情况比较差异无统计学意义。结论采用紫杉醇联合顺铂化疗能明显提高复发性卵巢患者的治疗效果,并且不会增加毒副作用,治疗过程中,对患者实施整体护理,加强临床观察,对提高治疗效果具有重要的意义。
出处 《现代中西医结合杂志》 CAS 2014年第29期3288-3289,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献9

  • 1邵淑丽,柳晓肃.卵巢上皮性癌的预后影响因素分析[J].中华妇产科杂志,2010,45(2):132-136. 被引量:12
  • 2Ozols RF,Bundy BN,Greer BE,et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:a Gynecologic Oncology Group study[ J]. J Clin Oncol,2003,21 ( 17 ) :3194 - 3200.
  • 3Schroder W, Zimny M, Rudlowski U, et al. The role of 18 F - fluoro- deoxyglucose positron emission tomography( 18F - FDG PET) in di- agnosis of ovarian cancer [ J ]. Int J Gynecol Cancer, 1999,9 (2) : 117 - 122.
  • 4Nakamoto Y,Saga T,Ishimori T,et al. Clinical value of positron e- mission tomography with FDG for recurrent ovarian cancer [ J ]. AJR,2001,176(6) :1449 - 1454.
  • 5Shamsunder S, Kumar L,Gupta S,et al. Chemotherapy in recurrent epithelial ovarian cancer ( EOC ) : an analysis of prognostic factors [Jl- J Obstet Gynaecol Res,2000,26(2) :215.
  • 6吴令英.卵巢上皮性癌的巩固治疗及复发治疗[J].中国实用妇科与产科杂志,2008,24(9):645-647. 被引量:11
  • 7燕鑫,陈春玲,张岩,廖秦平.61例复发性上皮性卵巢癌相关临床因素分析[J].中国妇产科临床杂志,2004,5(3):180-184. 被引量:4
  • 8Ferrero JM,Weber B, Geay JF, et al. Second-line chemotherapy w- ith pegylated liposomal doxorubicin and carboplatin is hilghly effec- tive in patients with advanced ovarian cancer in late relapse:a GI- NECO phase II trial[J]. Ann Oncol,2007,18(2) :263 -268.
  • 9陆勤美,许燕.紫杉醇联合吉西他滨治疗复发性卵巢癌患者的护理[J].解放军护理杂志,2011,28(20):52-54. 被引量:4

二级参考文献34

  • 1李孟达,李玉洁,黄永文,黄鹤.影响上皮性卵巢癌远期疗效的因素分析[J].癌症,2004,23(11):1306-1310. 被引量:19
  • 2江泽飞.紫杉醇在乳癌治疗中的应用[J].国外医学(肿瘤学分册),1995,22(2):99-101. 被引量:20
  • 3曹泽毅,于莎莎.妇科恶性肿瘤治疗后一年内未控与复发原因的研究——附全国61所医院1753例分析[J].中华妇产科杂志,1996,31(7):417-421. 被引量:21
  • 4Burger RA, Sill MW, Monk B J, et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study[ J ]. J Clin Oncol, 2007,25: 5165-5171.
  • 5Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial[J]. J Clin Oncol, 2003, 21 : 2460-2465.
  • 6Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup Trial of the AGOOVAR, the NCIC CTG, and the EORTC GCG[J]. J Clin Oncol, 2006,6:913-918.
  • 7Sorbe B. Swedish-Norwegian Ovarian Cancer Study Group: consolidation treatment of advanced (FIGO) stage ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy,chmotherapy, and no further treatment [J ]. Int J Gynecol Cancer, 2003,13 ( 3 ) : 278 -286.
  • 8Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? [ J ]. Gynecol Oncol, 1993,51:97-103.
  • 9孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2009.
  • 10Chan JK, Loizzi V, Lin YG, et aL Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol, 2003, 102 : 156-161.

共引文献24

同被引文献23

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部